VEGF protein (Active) (ab9571)
Our Abpromise guarantee covers the use of ab9571 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|CellDiff||CellDiff: Use at an assay dependent dilution.|
|Cellular activation||CellAct: Use at an assay dependent dilution. The protein can be used for dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0 ng/ml.|
|Functional Studies||FuncS: Use at an assay dependent dilution.|
|SDS-PAGE||SDS-PAGE: Use at an assay dependent dilution.|
- MGC70609Vascular Endothelial Growth FactorVascular endothelial growth factor A
- Vascular Permeability FactorVEGF-AVEGFAVEGFA_HUMANVPF
VEGF protein (Active) images
Human embryonic stem cells (H9) were differentiated both as embryoid bodies and monolayer cultures (on Matrigel) using a protocol described in Kennedy et al., 2006. BMP-4, FGF-basic (ab9596) and VEGF (ab9571) were sequentially added to the media to direct differentiation. These images were taken at day 8, where cell adhesion antigens CD31 (ab32457 in green) and CD34 (ab8536 in red) are abundant and represent primitive haematopoietic cells within the culture. Dapi staining is shown in blue.
References for VEGF protein (Active) (ab9571)
This product has been referenced in:
- Kim DS et al. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab 91:4603-11 (2006). Read more (PubMed: 16926250) »
- Rollin S et al. VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood 103:3789-97 (2004). Read more (PubMed: 14764537) »